Illumina has named Mostafa Ronaghi to the post of senior vice president and chief technical officer following the firm’s acquisition of Avatome, a DNA sequencing technology startup formed several months ago.
Ronaghi recently served as a senior research associate at the Stanford University Genome Technology Center. He also previously co-founded Swedish firm Pyrosequencing, later renamed Biotage. He was also a co-founder of ParAllele BioScience and Nextbio. Helmy Eltoukhy will also join Illumina, as director of Avantome sequencing development from Avantome, where he is president and CEO.
Illumina announced separately that it has appointed Stephen Pentoney to be vice president of assay and reagent development in the company’s Life Sciences Business Unit. In the new job, he will be responsible for leading assay application and development. Pentoney previously was involved in technology management and was a principal staff scientist at Beckman Coulter.
The Personalized Medicine Coalition has appointed David King and Pierre Cassigneul to its board of directors.
Cassigneul, who is president and CEO of XDx, formerly was an executive at Becton Dickinson, Stone Bridge Management, Ortho Diagnostics Systems, and Abbott Laboratories. David King is CEO and president of Laboratory Corporation of America, and he previously was a lawyer at Hogan & Hartson, where he was LabCorp’s outside counsel.
Washington University School of Medicine in St. Louis has named Barry Sleckman to be director of the Division of Genomic Medicine. Sleckman studies DNA repair and the development of the early immune system. He has served fellowships at Brigham and Women’s Hospital, the Dana-Farber Cancer Institute and the Center for Blood Research, and he joined WUSTL as an assistant professor of pathology and immunology a decade ago.